Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patients will experience local regional recurrence or distant metastasis. Lymphocytes are crucial immune cells in the human body, playing a key role in combating infections and tumor development. In recent years, an increasing body of research has indicated that lymphocyte depletion is a significant factor associated with p

Trial Details

NCT ID
NCT06596954
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • lymphocyte-sparing radiotherapy
  • conventional radiotherapy
Locations (sample)
  • Shanghai, China, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients are able to understand and are willing to participate in the trial, and a signed consent form can be obtained;
  • Pathologically confirmed esophageal squamous cell carcinoma;
  • locally advanced ESCC (cT3-4 or N+);
  • the age of patients should be more than 18 years, and less than 80 years;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →